Spyre Therapeutics is advancing SPY002, an investigational monoclonal antibody for inflammatory bowel disease that targets TL1A, a driver of persistent inflamma

Spyre Therapeutics is advancing SPY002, an investigational monoclonal antibody for inflammatory bowel disease that targets TL1A, a driver of persistent inflammation. The program underscores biotech’s push toward longer-acting therapies and novel immune pathways.